The deal values shares of ZymoGenetics, a Seattle-based biotech whose products in development include a Hepatitis C treatment, at $9.75 each. The stock closed Tuesday's session at $5.30, and was down 14% so far in 2010 prior to the announcement. ZymoGenetics's stock hasn't traded above $10 since March 2008.
Overall, the transaction is worth about $885 million. Net of ZymoGenetics' cash, the aggregate value of the deal is $735 million.
Bristol-Myers said the acquisition has already received the unanimous approval of the boards of both companies, and that shareholders representing roughly 37% of ZymoGenetics's outstanding common stock have entered agreements to support the deal and tender their shares to the offer."The acquisition of ZymoGenetics brings us full ownership of a promising investigational biologic that strengthens our very diversified Hepatitis C portfolio. Building on our leadership in virology, we are developing a strong portfolio to help patients with Hepatitis C," said Lamberto Andreotti, Bristol-Myers CEO, in a statement. "In addition, ZymoGenetics brings proven capabilities with therapeutic proteins and revenue from a marketed specialty surgical biologic." Bristol-Myers expects the deal to dilute earnings by 3 cents a share in fiscal 2010 and 7 cents a share in fiscal 2011. On August 3, ZymoGenetics posted a loss of $3.8 million, or 4 cents a share, for the second quarter ended in June with revenue totaling $37.7 million, up from $22.6 million in the same period a year earlier. In addition to pegylated-interferon lambda, ZymoGenetics's novel interferon in Phase IIb development for the treatment of Hepatitis C, the company's products also include Recothrom, a recombinant thrombin approved for use as a topical hemostat to control non-arterial bleeding, and a number of early clinical and pre-clinical oncology and immunoscience programs. --Written by Michael Baron in New York.
>To contact the writer of this article, click here: Michael Baron. >To submit a news tip, send an email to: firstname.lastname@example.org
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV